News › ZEISS · FDA approval for MTLawton – a new generation of bipolar forceps for electrosurgery
The surgical instrument reduces tissue sticking and allows a clear view of coagulation for efficient dissection.
ZEISS Medical Technology announces that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MTLawtonTM. This new bipolar forceps is based on a special copper alloy and potentially reduces sticking and subsequent burning of the tissue being dissected. Thanks to their extended shaft, the forceps also reduce visual restrictions on the surgical field and help surgeons to perform electrosurgical procedures efficiently.
By working closely with users, ZEISS medical technology succeeds in developing solutions that help doctors treat their patients in the best possible way. The development of the new bipolar forceps from ZEISS is based on close collaboration with Michael T. Lawton, one of the world’s leading neurosurgeons. »Compared to aluminum-based alloy bipolar forceps, the MTLawton is a true advancement in electrosurgery. Our copper-based alloy has superior thermal conductivity, improving hemostasis and reducing tissue adhesion,« emphasized Michael T. Lawton, MD, President and CEO, Chair, Department of Neurosurgery, Barrow Neurological Institute, Phoenix/Arizona (USA). »The MTLawton has noticeable benefits and also helps me with difficult arteriovenous malformations.«
Advantages for hemostatic treatment during minimally invasive procedures
During minimally invasive surgery, bipolar forceps are used for hemostasis (hemostasis) and tissue separation, among other procedures. When coagulating tissue, the high heat at the tips of the electrosurgical instruments can cause the instruments to stick to the tissue. MTLawton from ZEISS sets new standards in non-stick technology with its special copper-based alloy: the improved material conducts heat away from the silver-plated tips faster, potentially reducing sticking with subsequent tissue burning.
Optimal support during surgical procedures
Especially in neurosurgery, visualization and surgical instruments must go hand in hand to ensure that critical structures are not obscured. MTLawton from ZEISS, with its elegant shape and extended shaft, enables a clear view of the coagulation area – even in narrow and deep cavities. Thanks to its copper-based material, MTLawton from ZEISS is also robust and enables surgeons to handle tissue more efficiently.
»With the acquisition of Kogent Surgical in April of this year, ZEISS has expanded its range of surgical solutions for microsurgery. We are pleased to introduce the first surgical instrument from this acquisition to the market with FDA approval for MTLawton,« said Dr. Markus Weber, CEO of Carl Zeiss Meditec AG.
ZEISS will present MTLawton together with other solutions for neurosurgery at the Congress of Neurological Surgeons (CNS) in San Francisco from October 10–12, 2022.
Further information on electrosurgical instruments from ZEISS can be found here: www.zeiss.com/microsurgical-instruments